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Table S1. X-ray Data collection and Refinement Statistics. 
PR/EPX Complexes
Reservoir pH pH 6 pH 9 pH 9 
PDB ID 3TOF 3TOH 3TOG 
Crystal Form Orthorhombic Orthorhombic Monoclinic 
Space group P212121 P212121 P21 (β = 99°) 
a [Å] 51.287 (4) 51.266 (5) 51.195 (2) 
b [Å] 58.395 (7) 58.382 (9) 62.143 (7) 
c [Å] 61.072 (2) 61.304 (11) 58.768 (10) 
Volume [Å3] 182,900 183,480 184,660 
Maximum resolution (Å) 1.45 1.11 1.24 
Reflections (I/σ>2) 30,233 (23,666) 66,936 (52,396) 98,017 (76,725) 
R_free reflections 1512 3347 4901 
Restrains 20,916 20,952 40,620 
Parameters 15,687 15,714 30,465 
R_factor (I/σ>2) % 18 (17) 18 (17) 22 (20) 
R_free (%) 24.6 21.1  26.4 
Final model 
Protein atoms 1512 1512 3024 
Inhibitor atoms 38 39 78 
Water molecules 177 183 271 
Other atoms 16 12 12 
RMS Deviation 
Bond lengths (Å) 0.023 0.012 0.023 
Bond angles (Å) 0.024 0.017 0.021 
B-factor (Å2) 
Protein main chain 11.0 9.5 12.1 
Protein side chains 14.6 13.0 15.7 
Inhibitor 19.5 17.1 18.9 
Water molecules 25.1 22.4 23.4 
Other molecules 20.7 16.4 18.6 





Figure S1. (A) LIGPLOT of hydrophobic and hydrogen bond interactions between EPX and PR 
residues in PR/EPX with closed/unreacted epoxide ring; (B) LIGPLOT of hydrophobic and 
hydrogen bond interactions between EPX and PR residues in PR/EPX with triggered reaction on 
epoxide ring. 
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Table S2. Parameters used for Copasi simulation of diffusion, formation and complexation of 
serinol (SER) derivative in PR-EPX crystals (Figure 3 of manuscript). “Scenario 2” is equivalent to 
“Scenario 1” with reaction R7 omitted (formation of SER in PR/EPX crystal). 
 
Compartments
Compartments Solution (sol) Crystal (cry) a
Volume (cm3) 1.0 × 10−3 2.4 × 10−5 
a Assuming a typical crystal size of (0.4, 0.3, 0.2) mm3, corresponding to a A/Δx ratio of 0.41 cm [1], 
for the pH 6.0 orthorhombic crystal form reported in Table S1 (PDBID 3TOF). 
Molecular properties
Molecule NH3 EPX SER 
Cell accessible Volume Φ (fraction) 0.121 0.033 0.033 
D (cm2/s) b 2.9 × 10–5 3.9 × 10–6 3.9 × 10–6 
kD′(cm3/s) c 1.7 × 10–7 1.7 × 10–9 1.7 × 10–9 
b Calculated by HYDRO [2]. c kD′ = D Φ2A/Δx [1]. 
 Concentrations  
Molecule NH3 EPX SER PR PR/EPX PR/SER
Solution concentration (mM) 4 × 103 0.38 0    
Crystal concentration (mM) 0 0.38 0 0 3.6 0 
Diffusion Model Reactions
Label Expression Type k1 k−1 
R1 EPX(sol) = EPX(cry) M.A.(rev.) d 1.7 × 10–6 µL/s 1.7 × 10−6 µL/s 
R2 PR(cry) + EPX(cry) = PR/EPX(cry) M.A.(rev.) 5.8 × 102(mM s)−1 e 8.1 × 10–4 s-1 e 
R3 SER(sol) = SER(cry) M.A.(rev.) 1.7 × 10−6 µL/s 1.7 × 10−6 µL/s 
R4 PR(cry) + SER(cry) = PR/SER(cry) M.A.(rev.) 5.8 × 102(mM s) −1 e 8.1 × 10–4 s−1 e 
R5 EPX(sol) + NH3(sol) -> SER(sol) M.A.(irrev.) d 1.0 × 10−7(mM s) −1 f  
R6 NH3(sol) = NH3(cry) M.A.(rev.) 1.7 × 10−4 µL/s 1.7 × 10−4 µL/s 
R7 PR/EPX(cry) + NH3(cry) -> PR/SER(cry) M.A.(irrev.) 1.0 × 10−7(mM s) −1 f  
d COPASI Mass Action (M.A.) reversible or irreversible reaction [3]. e Assuming same values reported 
for Ritonavir inhibitor in [4]. f Evaluated from analogue oxirane ring opening reaction reported in [5]. 
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